Homopiperazine Derivatives as a Novel Class of Proteasome Inhibitors with a Unique Mode of Proteasome Binding

• Jiro Kikuchi,

  Affiliation Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯
• Naoya Shibayama,

  Affiliation Division of Biophysics, Department of Physiology, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯
• Satoshi Yamada,

  Affiliation Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯
• Taeko Wada,

  Affiliation Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯
• Masaharu Nobuyoshi,

  Affiliation Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯
• Tohru Izumi,

  Affiliation Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

  ⨯
• Miyuki Akutsu,

  Affiliation Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

  ⨯
• Yasuhiko Kano,

  Affiliation Division of Hematology, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan

  ⨯
• Kanako Sugiyama,

  Affiliation Protein Design Laboratory, Yokohama City University, Yokohama, Kanagawa, Japan

  ⨯
• Mio Ohki,

  Affiliation Protein Design Laboratory, Yokohama City University, Yokohama, Kanagawa, Japan

  ⨯
• Sam-Yong Park,

  Affiliation Protein Design Laboratory, Yokohama City University, Yokohama, Kanagawa, Japan

  ⨯
• Yusuke Furukawa

  * E-mail: furuyu@jichi.ac.jp

  Affiliation Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan

  ⨯